阿帕替尼治疗转移性肾细胞癌的疗效：一例病例报告及文献复习
The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature.
作者信息
Bi Jinling, Liu Haiyuan, Huang Yong
机构信息
Department of Oncology, The Second People's Hospital of He Fei, He Fei, An Hui, People's Republic of China.
出版信息
Int Med Case Rep J. 2017 Jul 4;10:223-227. doi: 10.2147/IMCRJ.S137484. eCollection 2017.
The aim of this study was to explore the effect of apatinib in the treatment of metastatic renal cell carcinoma (mRCC) and related adverse events. A case of mRCC was reported which recurred after surgery and roferon treatment. The patient was treated with apatinib at a dose of 500 mg orally, twice daily, 28 days/cycle. The metastatic lesions improved based on computed tomography after apatinib administration in the fourth and eighth month. The progression-free survival of the patient had increased almost to 8 months. The patient showed a good tolerance with only an adverse effect of mild-to-moderate hand-foot syndrome which was managed well. Apatinib is an option for mRCC after previous treatment. However, more and larger trials are still needed.
本研究旨在探讨阿帕替尼治疗转移性肾细胞癌（mRCC）的疗效及相关不良事件。报告了1例mRCC患者，该患者术后及使用干扰素治疗后复发。患者接受阿帕替尼治疗，口服剂量为500 mg，每日2次，每28天为1个周期。在服用阿帕替尼后的第4个月和第8个月，根据计算机断层扫描结果，转移病灶有所改善。患者的无进展生存期几乎增加到了8个月。患者耐受性良好，仅出现轻度至中度手足综合征这一不良事件，且处理得当。阿帕替尼是既往治疗后mRCC的一种选择。然而，仍需要更多且规模更大的试验。
Zotero 插件